PPT-AKT and SOX October results

Author : ray290 | Published Date : 2024-09-09

233 sat 165 passed 71 overall Pass mark was 705 29 sitters got above 80 8 of those gt90 68 failed and 33 of these were within 5 2 trainees on 6 th and 7 th attempts

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "AKT and SOX October results" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

AKT and SOX October results: Transcript


233 sat 165 passed 71 overall Pass mark was 705 29 sitters got above 80 8 of those gt90 68 failed and 33 of these were within 5 2 trainees on 6 th and 7 th attempts both passed. kinaseB(AKT)[24-27]. FOXOproteinsplayapivotalroleintheregulationof cellcyclearrest,celldeathandprotectionfromstress stimuli[23].PerturbationofFOXO October 2014 October 2014 October 2014 October 2014 . Presentation. July 2015. OTCQX: RESX. This presentation includes "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our anticipated future clinical and regulatory events, future financial/position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements can be identified by words such as “potential,” "may," "will," "should," "forecast,“ "project," "could," "expect," "believe," "estimate," "anticipate," "intend," "plan,“ “continue”, other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements in this presentation include, without limitation, statements regarding our current business strategies, the potential future commercialization of our product candidates, potential estimated market sizes for our product candidates, anticipated start dates, durations and completion dates, as well as potential future results, of our future clinical trials, anticipated designs of our future clinical trials, and anticipated future regulatory submissions and events. Uncertainties and risks may cause actual results to be materially different than those expressed in or implied by our forward-looking statements. Particular uncertainties and risks include, among others, uncertainties regarding our ability to license out our existing and license in additional products and technologies and the terms of such licenses; uncertainties involved in clinical testing, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent annual report on Form 10-K/A, subsequent quarterly reports on Form 10-Q and final prospectus dated July 31, 2014. All forward-looking statements in this presentation speak only as of the date of this presentation and we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.. SOS ENaCPIP3 C3G P IP 3 3G -P GAB1 Insuli PDK1/2 PKC Akt p70 PKC GA G p85 JAK NIK p PI3K Akt Tsc1 SOCS3 Shc NI K N GRB2 GRB 2 IRS-1 Fyn GRB10 Ras c-Raf MEK1/2 ERK PDE3B PKA SGK JNK SHP2 IRS-1 PTEN Pierre De . Meyts. = Chuck; . head . of research at Novo . Nordsk. Aug. Insulin. Insulin Receptor. Activates a series of downstream signaling cascades, leading to pleiotropic effects on:. How . does insulin . Shinichi Oka, PhD. Department of Cell Biology and Molecular Medicine. Rutgers New Jersey Medical School. MSB-I543. okash@njms.rutgers.edu. Objectives. Leptin. . Resistance. Obese. Insulin . Resistance. e-portfolio update. Feb. 2012. Came into effect from 2011. Clinical encounters: . At least 3 per month . Professional conversations: . No minimum but should include all meetings with supervisors, and any complaints or feedback. the Heart . f. rom . Ischemia . and . Reperfusion Injury . via . PI3K/. Akt. /. eNOS. Pathway. Yan Wu, . Xiangru. Lu, . Fuli. Xiang, and . Qingping. . Feng. Background. Ischemic Heart Disease (IHD). 1950 All Star Game. Willie Jones, 3B. Philadelphia Phillies. Willie Jones, 3B. Philadelphia Phillies. Puddin. ’ Head. Willie loved liver pudding and, reportedly, ate it before every game. Harold Reese, SS. MRCGP. . Zahid Asghar. 1 . Niro Siriwardena. 1 . . . Larcombe. J. 2. , . Elfes. C. 2. , . Neden. K. 2. , Salim A. 2. , Smalley D. 2. , Richardson J. 2. , Blow C. 2. 1 . University . of Lincoln, . Friday, April 23, 2010. 9:30 AM - 6 PM. Sponsored by Yahoo!, CSE, and SI. www.eecs.umich.edu/dm10. “U.S. households consumed approximately 3.6 . zettabytes. *. of information in 2008”. 1 . zettabyte. Grazia Arpino. Università di Napoli Federico II. Current. Endocrine . Therapy. :. Tamoxifen. ; . aromatase. . inhibitors. Limited. . by. “de-novo” or “. acquired. ” . endocrine . resistance. 33 These concerts are generously sponsored by Cindy Sargent.Sponsorship of the music director and related programs is provided in part by a generous gift from the Zell Family Foundation.CSO Tuesday s Alison Holiday. Alzheimer’s Disease (AD). Leptin. Leptin. 116-130. prevents copper induced cell death. Crystal violet assay on leptin and leptin. 116-130. treated cells with . copper. CuCl. 2. -treated.

Download Document

Here is the link to download the presentation.
"AKT and SOX October results"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents